Business Description
Tenax Therapeutics Inc
NAICS : 541714
SIC : 8731
ISIN : US88032L6056
Total Employee Number:
16Description
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.93 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 87 | |||||
3-Year EPS without NRI Growth Rate | 86.9 | |||||
3-Year FCF Growth Rate | 88.7 | |||||
3-Year Book Growth Rate | -41.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -4.03 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 43.11 | |||||
9-Day RSI | 30.1 | |||||
14-Day RSI | 27.16 | |||||
3-1 Month Momentum % | -86.97 | |||||
6-1 Month Momentum % | -90.52 | |||||
12-1 Month Momentum % | -77.53 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 15.07 | |||||
Quick Ratio | 15.07 | |||||
Cash Ratio | 14.61 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -61.79 | |||||
ROA % | -58.15 | |||||
ROIC % | -9023.15 | |||||
3-Year ROIIC % | 10007.06 | |||||
ROCE % | -63.54 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.52 | |||||
Price-to-Tangible-Book | 0.52 | |||||
EV-to-EBIT | 0.73 | |||||
EV-to-Forward-EBIT | 0.64 | |||||
EV-to-EBITDA | 0.73 | |||||
EV-to-Forward-EBITDA | 0.61 | |||||
EV-to-Forward-Revenue | 0.07 | |||||
EV-to-FCF | 1.05 | |||||
| Price-to-Net-Current-Asset-Value | 0.52 | |||||
| Price-to-Net-Cash | 0.54 | |||||
Earnings Yield (Greenblatt) % | 136.99 | |||||
FCF Yield % | -66.12 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TENX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Tenax Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.48 | ||
| Beta | -0.3073 | ||
| 3-Year Sharpe Ratio | -0.16 | ||
| 3-Year Sortino Ratio | -0.21 | ||
| Volatility % | 114.28 | ||
| 14-Day RSI | 27.16 | ||
| 14-Day ATR ($) | 0.560061 | ||
| 20-Day SMA ($) | 1.9175 | ||
| 12-1 Month Momentum % | -77.53 | ||
| 52-Week Range ($) | 1.31 - 19.4 | ||
| Shares Outstanding (Mil) | 37.42 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Tenax Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Tenax Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-03-10 | In 180 days | ||
| Third quarter earnings results for 2026 | 2026-11-12 | In 62 days | ||
| Guidance call for 2026 | 2026-09-09 08:35 | 1.98 (+1.54%) | ||
| Tenax Therapeutics Phase 3 LEVEL Topline Results | 2026-08-10 08:00 | 13.44 (-0.44%) | ||
| Second quarter earnings results for 2026 | 2026-07-31 | 15.10 (+1.89%) | ||
| General meeting for 2026 | 2026-06-02 09:00 | 11.97 (+1.44%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 11.95 (+2.14%) | ||
| Guidance call for 2026 | 2026-03-10 14:20 | 11.15 (+4.89%) | ||
| Annual report for 2025 | 2026-03-10 | 11.15 (+4.89%) | ||
| Guidance call for 2026 | 2026-02-11 12:30 | 12.79 (-8.64%) |
Show
Entries
Tenax Therapeutics Inc Frequently Asked Questions
What is Tenax Therapeutics Inc(TENX)'s stock price today?
The current price of TENX is $1.86. The 52 week high of TENX is $19.40 and 52 week low is $1.31.
When is next earnings date of Tenax Therapeutics Inc(TENX)?
The next earnings date of Tenax Therapeutics Inc(TENX) is 2026-11-12 Est..
Does Tenax Therapeutics Inc(TENX) pay dividends? If so, how much?
Tenax Therapeutics Inc(TENX) does not pay dividend.
Press Release
Headlines
See More- 1
Aug 30, 2026
Tenax finds benefit in sicker patient subgroup after Phase 3 trial miss
Seeking Alpha • 2:01pm
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers